A to Z / Metabolic / weight loss

Survodutide

Also known as BI 456906.

Best known for The GLP-1/glucagon dual agonist with a liver focus

Evidence★★☆☆☆

Safety dataPoorly characterised

Route Weekly injection

United StatesInvestigational

AustraliaNot approved

as at 16 September 2026

What it is

Survodutide is an investigational dual agonist targeting the GLP-1 and glucagon receptors. It is in phase-3 development for obesity and for metabolic dysfunction-associated steatohepatitis (MASH), and it is not approved anywhere yet.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Retatrutide, Tirzepatide, Mazdutide, Semaglutide

Related entries

RetatrutideThe next-generation weight-loss drug that isn't approved yet · Evidence ★★☆☆☆
TirzepatideThe most effective approved weight-loss drug · Evidence ★★★★★
MazdutideThe dual agonist developed primarily in China · Evidence ★★☆☆☆
SemaglutideThe drug that changed obesity treatment · Evidence ★★★★★

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Survodutide. It is not medical advice and not a recommendation to use it.